Business briefs: Roche, Gilead

Share this article:

An anonymous complaint to UK industry self-policing arm PCMPA (Prescription Medicines Code of Practice Authority) alleges Roche employees behaved inappropriately while attending an overseas medical conference. The complainant alleged that “two very senior Roche personnel” supplied round after round of shots to a delegation of doctors, and that the alcohol “flowed like hot lava, unstoppably.” Roche responded that “Staff did not go to the bar with any health professionals nor did they arrange to meet any.” The panel found no evidence that the Roche staffers “had provided any hospitality to UK health professionals as alleged” and so found no violation.

In Gilead's Q4 earnings call, CFO Robin Washington said intellectual property for its new hepatitis C compound “is domiciled in Ireland,” which, The Wall Street Journal reported, could effectively cut Gilead's tax rate to by 5-7%, due to an Irish policy which exempts income from taxes on patent royalties. With analysts forecasting worldwide sales of $7 billion a year for Gilead – this off-shore move could mean an additional $500 million a year in profit for blockbuster hopeful sofosbuvir (AKA PSI-7977). The AIDS Healthcare Foundation labeled Gilead a “tax-supported tax evader.” AHF president Michael Weinstein roared: “This latest move should come as no surprise as Gilead has continually pursed price hikes and exploited patent loopholes to maximize earnings on its lifesaving HIV/AIDS Drugs … by charging government-funded programs exorbitantly high prices that limit access.”           

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.